1. Introduction {#s0005}
===============

The pathogenesis of type-2 diabetes mellitus (T2DM) mainly involves abnormalities in insulin secretion and action, the so called insulin resistance (IR) ([@b0215]). The exact mechanism of IR is multifactorial and has not been precisely established however certain factors such as metabolic syndrome, obesity, dyslipidemia and hyperinsulinemia have been implicated with IR ([@b0215], [@b0105], [@b0155]). Over the time, IR and hyperinsulinemia often lead to T2DM or pre-diabetes because the beta cells fail to keep up with the body\'s increased need for insulin ([@b0165]). It is also probable that chronic inflammation may trigger the onset of IR and subsequently the emergence of T2DM ([@b0185]).

Both T2DM and metabolic syndrome are highly prevalent in Saudi Arabia ([@b0040], [@b0120], [@b0035]). Bahijri et al ([@b0050]) have suggested that screening of IR in the general population is important for developing strategies to reduce the prevalence of T2DM. Previous studies have shown significant correlations between IR and ghrelin ([@b0015]); adiponectin ([@b0020]); leptin ([@b0110]); resistin ([@b0030]), C-reactive protein ([@b0025]), triglycerides ([@b0145]), thyroid hormones ([@b0140]), vitamin D ([@b0005], [@b0160]), and liver enzymes ([@b0085], [@b0045]). [@b0060] have shown that HbA1c may serve as a simple and reliable marker for IR in adults with normal glucose tolerance. [@b0205] observed an inverse association between lipoprotein-a and IR as well as metabolic syndrome that precedes an overt T2DM diagnosis.

C-peptide is a byproduct of the insulin synthesis from pro-insulin and roughly indicates the extent of insulin production and release. C-peptide is a biological active compound ([@b0095]) and also serves as an important diagnostic biomarker ([@b0075], [@b0055], [@b0070], [@b0220]). Recently, C-peptide has been suggested as a strong indicator of metabolic syndrome suggesting the importance of this biomolecule in diagnosis of metabolic syndrome ([@b0100]). Because both metabolic syndrome and IR are associated with elevated risk for developing T2DM, it would be intriguing to investigate the biomarker potential of C-peptide for screening of IR prone individuals such as pre-diabetics and diabetics.

The homeostasis model assessment insulin resistance (HOMA-IR) developed by [@b0170], is a convenient and widely used method for the estimation of IR. In this study, we examined the associations between HOMA-IR and fasting blood glucose (FBG), glycated hemoglobin (HbA1c), insulin and C-peptide in type-2 diabetic patients and healthy controls and evaluated the biomarker potential of C-peptide for screening of IR in diabetic and non-diabetic individuals.

2. Materials and methods {#s0010}
========================

This study comprised a total of 47 T2DM patients and 38 non-diabetic controls who visited the clinics of Prince Sultan Military Medical City, Riyadh, Saudi Arabia. There were 27 males and 20 females in diabetic group and 23 males and 15 females in control group. The average age of the diabetic patients and control subjects were 41.21 ± 4.73 years and 40.79 ± 3.95 years, respectively. The main inclusion criteria for diabetic patients were being a Saudi national and affected with type-2 diabetes. The exclusion criteria included severe chronic illnesses, infections and pregnancy.

Venous blood samples from all the subjects were collected in serum separator tubes after at least 8 h fasting. The sera were analyzed for fasting blood glucose (FBG), glycated hemoglobin (HbA1c), insulin and C-peptide using an autoanalyzer (Roche Modular P-800, Germany). HOMA-IR was calculated using the following equation; fasting insulin (µU/ml) × fasting glucose (mmol/L)/22.5 as reported earlier ([@b0170], [@b0210]).

The data were analyzed by SPSS version 10. Pearson's correlation test was performed to examine various correlations. Independent samples Student's *t*-test (2-tailed) was used to compare the means of different parameters between controls and diabetic patients. P values less than 0.05 were considered as statistically significant.

3. Results {#s0015}
==========

The level of FBG was significantly higher in diabetic patients (11.51 ± 0.55 mmol/L) as compared to controls (5.19 ± 0.13 mmol/L) ([Fig. 1](#f0005){ref-type="fig"}a). Diabetic patients had poor glycemic control and their HbA1c levels were significantly higher (9.49 ± 0.31% versus 6.04 ± 0.18%) than normal subjects ([Fig. 1](#f0005){ref-type="fig"}b). Although insulin levels were comparatively higher in diabetic patients (25.25 ± 5.39 µU/mL) than controls (16.71 ± 2.02 µU/mL), this difference was not statistically significant ([Fig. 2](#f0010){ref-type="fig"}a). Diabetic patients showed a significantly high level of HOMA-IR (11.49 ± 2.10) as compared to normal subjects (3.95 ± 0.46) ([Fig. 2](#f0010){ref-type="fig"}b). In diabetic patients, 16 of 47 patients (34.04%) had HOMA-IR \> 10 as compared to only 2 of 38 controls (5.26%). There was no significant difference in C-peptide levels between diabetic patients (951.17 ± 100.69 mmol/L) and controls (861.18 ± 63.66 mmol/L) ([Fig. 3](#f0015){ref-type="fig"}).Fig. 1Levels of (a) fasting blood glucose and (b) HbA1c in controls and diabetic patients. ^\*^P \< 0.001 versus control group, *t*-test.Fig. 2Levels of (a) serum insulin and (b) insulin resistance in controls and diabetic patients. ^\*^P \< 0.01 versus control group, *t*-test.Fig. 3Serum C-peptide levels in controls and diabetic patients.

There were highly significant correlations between HOMA-IR and insulin in both diabetic patients (R = 0.961, P = 0.001) and control subjects (R = 0.975, P = 0.001) ([Table 1](#t0005){ref-type="table"}). C-peptide was also significantly correlated with HOMA-IR in diabetic patients (R = 0.652, P = 0.001) and controls (R = 0.500, P = 0.001). Although HOMA-IR was not correlated with HbA1c in diabetic patients (R = -0.070, P = 0.259), it was significantly correlated with HbA1c in normal subjects (R = 0.355, P = 0.029). Both age and gender were not correlated with HOMA-IR, irrespective of patient or control groups ([Table 1](#t0005){ref-type="table"}).Table 1Correlations between insulin resistance (HOMA-IR) and other variables.VariableDiabetic patients onlyNon-diabetic controls onlyRPRPAge−0.1400.347−0.0190.909Gender0.2020.1730.0070.966FBG−0.0410.7840.2440.140HbA1c−0.1700.2590.3550.029[\*](#tblfn1){ref-type="table-fn"}Insulin0.9610.001[\*](#tblfn1){ref-type="table-fn"}0.9750.001[\*](#tblfn1){ref-type="table-fn"}C-peptide0.6520.001[\*](#tblfn1){ref-type="table-fn"}0.5000.001[\*](#tblfn1){ref-type="table-fn"}[^1]

4. Discussion {#s0020}
=============

Several studies have shown that IR is a strong predictor for the future development of diabetes ([@b0165], [@b0150]). Moreover, current interest in IR and metabolic syndrome is because of their ever-growing incidence and the associated mortality and morbidity due to cardiovascular events, even in non-diabetic subjects ([@b0090]). Thus, a timely identification of IR in non-diabetic population is of a great importance in a community-based strategy to reduce the upcoming prevalence of T2DM, keeping in mind that interventional studies have demonstrated that preservation of b-cell function decreases the transformation of pre-diabetes to diabetes ([@b0135], [@b0065]). It has been suggested that the method of choice for the screening of IR should be suitable for a large-population study, require one blood sample and having a high level of reproducibility and prediction power ([@b0050]).

Our results showed significantly high levels of FBG and HbA1c in T2DM patients as compared to control subjects ([Fig. 1](#f0005){ref-type="fig"}) indicating a reluctant approach for glycemic control in Saudi individuals ([@b0200], [@b0125], [@b0010]). We observed that serum insulin levels were comparatively higher in T2DM patients than non-diabetic individuals ([Fig. 2](#f0010){ref-type="fig"}). A previous study has shown significantly higher levels of serum insulin in Saudi T2DM patients as compared to healthy controls ([@b0115]). The HOMA-IR was found to be significantly high in T2DM patients as compared to controls ([Fig. 2](#f0010){ref-type="fig"}), which is supported by previous studies on Saudi T2DM patients ([@b0015], [@b0190]). In our study, severe IR (HOMA-IR \> 10) was observed in 34.04% of diabetic patients and 5.26% of non-diabetic controls. A recent study on 107 T2DM patients and 101 controls showed the IR frequency of 46.7% in diabetic patients and 5.9% in controls ([@b0015]).

There were no correlations between IR and age, gender or FBG in the subgroups of T2DM patients and non-diabetic controls; however, HbA1c was significantly correlated with IR, only in non-diabetic individuals ([Table 1](#t0005){ref-type="table"}). In a previous study from Saudi Arabia, HOMA-IR values were not associated with age, gender or disease duration [@b0015]. [@b0050] observed that adiposity, but not gender, is a risk factor for IR in healthy adults from Saudi Arabia. A comparative analysis of subjects with normal glucose tolerance (N = 24), impaired fasting glucose (N = 12), impaired glucose tolerance (N = 12), and T2DM (N = 13) showed that HbA1c was more strongly associated with IR in only normal glucose tolerance group ([@b0060]). [@b0015] observed that HbA1c levels were significantly higher in T2DM subjects with IR than in those without IR; moreover, HbA1c was not correlated with HOMA-IR.

The striking observation of this study was a significant correlation between C-peptide and IR in both T2DM patients and non-diabetic individuals ([Table 1](#t0005){ref-type="table"}) despite C-peptide levels did not differ between these two subgroups ([Fig. 3](#f0015){ref-type="fig"}). C-peptide levels were found to be significantly higher in healthy subjects with IR than in those without IR ([@b0015]). High levels of fasting C-peptide pose a risk factor for the development of atherosclerosis in both non-diabetic and diabetic persons ([@b0130], [@b0195]). [@b0025] observed that C-peptide levels were significantly higher in patients with metabolic syndrome irrespective of gender difference. [@b0080] have shown that fasting C-peptide is significantly correlated with several markers of metabolic syndrome in obese adults. Thus, C-peptide may serve as a multi-modal biomarker to identify risky individuals for IR, T2DM, atherosclerosis and metabolic syndrome. It has been recommended that screening for T2DM should begin at the age of 45 years and then be repeated on 3 year intervals; however among the risky individuals, it should begin sooner and be more frequent ([@b0180]). [@b0015] have suggested the need of a parallel screening for IR as it can be used to trace IR milestones and the progress of the disease with increased age and disease duration.

5. Conclusion {#s0025}
=============

Insulin resistance is highly prevalent in T2DM patients from Saudi Arabia. Both FBG and HbA1c levels do not reflect the intensity of HOMA-IR in T2DM patients. HOMA-IR is also unaffected by age and gender. Serum C-peptide may be used as an appropriate index for detecting IR in community-based surveys. A longer half-life of C-peptide (approximately 5-fold) than insulin ([@b0175]) also favors its biomarker utility with less fluctuation.
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[^1]: Statistically significant.
